HIV infection, antiretroviral therapy, and CD4+ cell count distributions in African populations.
about
Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison studyClinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection--a quantitative review.Joint estimation of CD4+ cell progression and survival in untreated individuals with HIV-1 infection.Development, calibration and performance of an HIV transmission model incorporating natural history and behavioral patterns: application in South Africa.Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it?Comparative effectiveness of HIV testing and treatment in highly endemic regions.Antiretroviral therapy for tuberculosis control in nine African countries.Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis.Info-gap management of public health Policy for TB with HIV-prevalence and epidemiological uncertaintyPopulation-based CD4 counts in a rural area in South Africa with high HIV prevalence and high antiretroviral treatment coveragePredictions of CD4 lymphocytes' count in HIV patients from complete blood count.Normal Range of CD4 Cell Counts and Temporal Changes in Two HIVNegative Malawian Populations.Brief report: HIV-1 transmissions during asymptomatic infection: exploring the impact of changes in HIV-1 viral load due to coinfections.Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy.Treatment as prevention: preparing the wayAntiretroviral therapy initiated soon after HIV diagnosis as standard care: potential to save lives?Are long-lasting insecticide-treated bednets and water filters cost-effective tools for delaying HIV disease progression in Kenya?Achieving universal access for human immunodeficiency virus and tuberculosis: potential prevention impact of an integrated multi-disease prevention campaign in kenyaModeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis.Switch from 200 to 350 CD4 baseline count: what it means to HIV care and treatment programs in Kenya.Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African womenUpdates to the Spectrum/Estimation and Projection Package (EPP) model to estimate HIV trends for adults and children.HIV-1/parasite co-infection and the emergence of new parasite strains.CD4 Cell Count: Declining Value for Antiretroviral Therapy Eligibility.Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings.Epidemiological Trends for HIV in Southern Africa: Implications for Reaching the Elimination Targets.Australian prescribers' perspectives on ART initiation in the era of "treatment as prevention".Impact of Targeted Tuberculosis Vaccination Among a Mining Population in South Africa: A Model-Based Study.Cost-Effectiveness of Community-based Human Immunodeficiency Virus Self-Testing in Blantyre, Malawi.
P2860
Q28534568-C6D51CEC-506B-4079-B31B-DDB6DD3ED7CAQ33470290-AB582D84-228E-4FDA-8E11-23A87507C57EQ33631159-14CC67BF-685B-43BA-B0BC-80CEC95EC55CQ33670446-3DDC8E4B-DF5E-404C-AD12-F921F8305A81Q33795967-E1E9051B-11F4-4838-BCE7-2004B1A55C3AQ34064269-3D3E2042-749D-4DD0-9158-4D495D1E47ECQ34320245-BE63CF8B-691C-4217-BF91-967094924F29Q34387168-C92D0F07-2C65-4AB9-87D8-BC8E1E9D0725Q34515059-9BEAF382-EEDB-4E3B-80A9-80CC794AF00FQ34875528-A7DDD85E-C335-430B-834F-0AA6CC4261D4Q34986925-37FF5807-A4C4-4251-ADD6-7088B17E94F3Q35182289-FE670C1A-A7EC-4528-9803-5E6B25FF2822Q35288465-99A7D25D-48AB-4F81-9E94-D32C819C2B9BQ35297467-6F54FD98-1BDF-43C1-87D2-94DED43A4AB6Q35357663-7726F985-9226-44C0-8557-49505CD019F3Q35557314-ED8A7E8B-C7BB-4C42-ACEA-AE92B6C4708DQ35722064-144CCEEA-FB66-4997-8618-8DDECBB79E54Q35960185-A66DD71A-ABF6-4948-8E99-3F7966926E8BQ36070976-1F33B368-9072-4BB8-9327-EBAFC3199783Q36325644-54470DA4-3841-4FE1-A00B-E31F2FD54E08Q36422444-EA2A2895-1ABA-480D-A3AC-5782A9E5A448Q36440560-5C140975-D36A-4910-AC81-809A8FBD33A1Q37120966-BC9B0C74-3EB7-4FB5-9259-C3039D41EB2FQ37220730-20C88D90-350A-4861-991B-825995EF1E7AQ37702101-D196899B-0833-41CE-8741-FE56958BFD91Q38452179-E21D3ABA-EB40-469D-B7B0-BCCBF19B83F9Q42275177-3B37BD8A-2FE6-456A-8A02-F20A73645138Q46271978-172712A1-CD11-4396-A1CA-2D9A1F2C3D09Q47599722-01B19454-FBC2-4D61-82FD-A34B7C6D6EC3
P2860
HIV infection, antiretroviral therapy, and CD4+ cell count distributions in African populations.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
HIV infection, antiretroviral ...... utions in African populations.
@en
HIV infection, antiretroviral ...... utions in African populations.
@nl
type
label
HIV infection, antiretroviral ...... utions in African populations.
@en
HIV infection, antiretroviral ...... utions in African populations.
@nl
prefLabel
HIV infection, antiretroviral ...... utions in African populations.
@en
HIV infection, antiretroviral ...... utions in African populations.
@nl
P2093
P356
P1476
HIV infection, antiretroviral ...... utions in African populations.
@en
P2093
Bertran Auvert
Eleanor Gouws
Eline L Korenromp
George P Schmid
P304
P356
10.1086/508206
P407
P577
2006-10-03T00:00:00Z